Instrument Inactif

Communiqués Renovacor, Inc.

Actions

RCOR

US75989E1064

Recherche biotechnologique et médicale

Communiqués

10/11/22	RENOVACOR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
14/10/22	RENOVACOR, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
11/10/22	Renovacor Announces Upcoming Presentation at the 29th European Society of Gene and Cell Therapy Congress	AQ
10/10/22	Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress	BU
27/09/22	Renovacor Announces Upcoming Presentation at Keystone Symposia's Heart Failure, Mechanisms and Therapies Conference	AQ
26/09/22	Renovacor Announces Upcoming Presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference	BU
22/09/22	RENOVACOR, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
20/09/22	RENOVACOR, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20/09/22	Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy	BU
08/08/22	Renovacor : Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K	PU
08/08/22	RENOVACOR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
08/08/22	Renovacor Reports Second Quarter 2022 Financial Results and Provides Corporate Update	BU
12/07/22	RENOVACOR, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
12/07/22	Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy	BU
24/06/22	RENOVACOR, INC. Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K/A)	AQ
03/06/22	RENOVACOR, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
01/06/22	RENOVACOR, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
01/06/22	Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research	BU
26/05/22	RENOVACOR, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
12/05/22	RENOVACOR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
12/05/22	Renovacor Reports First Quarter 2022 Financial Results and Provides Corporate Update	BU
28/03/22	RENOVACOR, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
28/03/22	Renovacor Announces the Appointment of Fred Driscoll as Chief Financial Officer	BU
24/03/22	Renovacor : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update - Form 8-K	PU
24/03/22	RENOVACOR, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ